Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of milvexian versus enoxaparin for prevention of venous thromboembolism after elective total knee replacement
2018-004237-32Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of milvexian in venous thromboembolism (VTE), sponsored by Janssen Pharmaceutical. Started Mar 2019; status: completed.
02
Drugs
milvexian
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2018-004237-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004237-32.